Comparing Halozyme Therapeutics (HALO) and Eisai (ESALY)

Halozyme Therapeutics (NASDAQ: HALO) and Eisai (OTCMKTS:ESALY) are both companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Risk and Volatility

How to Become a New Pot Stock Millionaire

Halozyme Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Eisai has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500.

Earnings & Valuation

This table compares Halozyme Therapeutics and Eisai’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Halozyme Therapeutics $316.61 million 8.89 $62.97 million $0.45 43.53
Eisai $4.99 billion 3.84 $366.03 million $1.27 50.79

Eisai has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Eisai, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Halozyme Therapeutics and Eisai, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 1 3 4 0 2.38
Eisai 0 0 0 0 N/A

Halozyme Therapeutics currently has a consensus price target of $19.75, suggesting a potential upside of 0.82%. Given Halozyme Therapeutics’ higher probable upside, research analysts clearly believe Halozyme Therapeutics is more favorable than Eisai.

Profitability

This table compares Halozyme Therapeutics and Eisai’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics 19.89% 89.83% 17.39%
Eisai 5.12% 4.74% 2.78%

Institutional & Insider Ownership

85.6% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Eisai shares are held by institutional investors. 16.8% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dividends

Eisai pays an annual dividend of $1.24 per share and has a dividend yield of 1.9%. Halozyme Therapeutics does not pay a dividend. Eisai pays out 97.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Halozyme Therapeutics beats Eisai on 10 of the 15 factors compared between the two stocks.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

About Eisai

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company’s business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The other segment consists of pharmaceutical raw materials, logistics services and business services businesses.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply